Navigation Links
BUSM professor awarded $13.3 million to study potential treatments to prevent STDs
Date:8/12/2011

(Boston) Deborah Anderson, PhD, professor of obstetrics and gynecology and microbiology at Boston University School of Medicine (BUSM) is co-leading a new study funded by a five-year $13.3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID). Anderson will investigate the vaginal use of human monoclonal antibodies manufactured transiently in tobacco plants (called "plantibodies") to prevent sexually transmitted infections caused by Herpes Simplex Virus (HSV) and the Human Immunodeficiency Virus (HIV).

The production of human monoclonal antibodies and other proteins in plants is intended to provide a low-cost and large-capacity manufacturing system that could ensure an affordable supply of antibodies, vaccines and other biopharmaceuticals for at-risk populations throughout the world, including developing countries.

The research team will develop ring, film and barrier formulations to deliver the antibodies and conduct preclinical testing in vitro and in vivo using animal models to evaluate safety and antimicrobial (HSV, HIV) efficacy. The plantibodies will be tested for safety and duration of activity in a human pre-phase I clinical trial as a first step towards their use as vaginal microbicides to prevent HSV and HIV infections in women.

"We hope that this research will lead to novel ways of preventing sexually transmitted diseases, which are epidemic in the US and worldwide and have far reaching health, social and economic consequences," said Anderson. "In addition, we will be breaking ground for the potential use of plantibodies to prevent other diseases caused by pathogens that cross mucosal membranes, such as rhinoviruses (common cold) and influenza (flu), as well as dangerous emerging pathogens like the Ebola virus (hemorrhagic fever)."

The grant was awarded through the NIAID-funded Integrated Preclinical/Clinical Program for HIV Topical Microbicides. Kevin Whaley, PhD, at Mapp Biopharmaceuticals in San Diego and Thomas Moench, MD, at ReProtect Inc. in Baltimore, are the main collaborators on this research study.

The research will be conducted by a consortium of investigators at Boston University Medical Campus, University of North Carolina, Johns Hopkins University, Brown University, Emory University, Fenway Community Health, ReProtect LLC, Kentucky BioProcessing LLC, Auritec Pharmaceuticals Inc., Aridis Pharmaceuticals and Mapp Biopharmaceutical Inc.


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. National Science Foundation grants Clemson professors award to develop nanoprobes
2. University professor stresses links between US Navy sonar and whale strandings
3. Minnesota ecology professor wins international award for biodiversity and biofuels research
4. NJIT professors research suggests changes in underwater data communications
5. 2 Alexander von Humboldt professorships go to LMU Munich
6. Top biophysics award to Professor Ray Norton
7. University of Leicester professor adds new perspective to rainforest debate
8. NJIT professor finds engineering technique to identify disease-causing genes
9. Chemistry professor 1 of only 3 at UH to achieve prestigious AAAS status
10. Florida professor creates endowment for insect scientists
11. Dinner, lecture series to honor legacy of distinguished UH professor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/19/2017)... Jan. 18, 2017 BD (Becton, Dickinson and Company) (NYSE: ... that it will host a live webcast of its Annual Meeting ... The webcast can be accessed from the BD ... through Tuesday, January 31, 2017. ... About BD BD is a global medical ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market by Technique ... Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by ... USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
Breaking Biology Technology: